Omecamtiv mecarbil (OM) enhances systolic function in vivo by directly binding the myosin cross-bridges (XBs) in the sarcomere. However, the mechanistic details governing OM-induced modulation of XB behavior in failing human myocardium are unclear.
P
rogression of heart disease to end-stage heart failure (HF) is often the result of long-term maladaptive remodeling coupled with deteriorating cardiomyocyte function. Although the fundamental pathophysiological mechanisms that lead to HF are not completely understood, 1 a common feature of many forms of HF is decreased contractility, leading to diminished force generation at the cardiomyocyte level and diminished systolic performance at the whole-heart level. Importantly, despite significant therapeutic advances, the clinical course of HF patients remains unacceptably poor and continues to pose major clinical challenges. 2, 3 Current therapies aimed at increasing cardiac contractility have not improved long-term outcomes and carry the potential for undesirable adverse side effects related to activation of signaling pathways that enhance cardiomyocyte intracellular Ca 2+ concentrations. 2, 4, 5 Thus, recent efforts 6, 7 have focused on designing HF therapies that circumvent complex signaling pathways and instead directly target the force-generating contractile machinery of the myofilaments.
In this regard, omecamtiv mecarbil (OM), a molecule that selectively binds the catalytic domain of myosin, has gained significant attention because of its potentially beneficial effect on systolic function in HF patients. 5, 7, 8 Early clinical trials have demonstrated that OM augments systolic indices such as systolic ejection time (SET), stroke volume, and ejection fraction 5 without altering cardiomyocyte Ca 2+ transients. 9 The mechanisms underlying OM-induced force enhancements have been linked to an enhanced stability of the actin-bound myosin cross-bridges (XBs), 10 slowed strain-induced XB detachment from actin, 11, 12 and slowed shortening velocity, 13 which act to prolong the XB duty cycle.
14 Additionally, OM has been shown to accelerate phosphate release 10, 15 but concomitantly delays the XB power stroke and actin-activated ATP turnover, 15 thereby, maintaining XBs in a strongly bound state. Thus, in theory, a prolonged XB duty cycle should reduce ATP utilization and improve contractile efficiency, 11 thereby reducing workload in failing hearts.
Initial clinical trials have demonstrated that OM induces dose-dependent increases in stroke volume and fractional shortening in healthy volunteers 5 and HF subjects without adverse side effects. 2, 7 Despite these early positive results, the functional impact of OM on dynamic XB behavior at the cellular level has not been established, and there are no studies that have systematically examined the impact of OM on myofilament contractile function in human failing myocardium. This information would be valuable because it has been shown that failing human myocardium displays pathological remodeling, altered contractile protein phosphorylation, and diminished force-generating capacity 16, 17 -factors that could potentially modify the impact of OM on XB behavior. Thus, in this study, we tested whether the dose-dependent impact of OM on XB behavior differs in ventricular myocardium isolated from donor and failing hearts.
METHODS
An expanded Methods section is available in the Data Supplement.
Ethical Approval and Procurement of Human Myocardial Tissue Samples
Normal, nonfailing (donor), and failing left ventricular human cardiac tissue samples were collected and stored until used for experiments as per the approved guidelines of the University of Sydney.
Determination of Sarcomeric Protein Expression and Phosphorylation Levels
Coomassie and Pro-Q Diamond phosphoprotein staining was performed to quantify myofilament protein expression and phosphorylation in the cardiac samples as described previously 18, 19 ( Figure 1A and 1B). Quantification of β-myosin heavy chain expression (n=6 per group; Figure 1C ) was performed
WHAT IS NEW?
• We investigated if omecamtiv mecarbil (OM) affects actomyosin cross-bridge (XB) behavior similarly in healthy and pathologically remodeled human heart failure (HF) myocardium.
• Dose-dependent impact of OM on XB function was examined in detergent-skinned myocardial preparations from donor and HF hearts.
• OM significantly enhanced XB recruitment to a force-bearing state in HF myocardium, effectively reducing the force deficit of HF myocardium compared to donor myocardium. • However, OM-induced force enhancement in HF myocardium was accompanied by slowed peak force development and XB cycling compared with donor myocardium, particularly at higher OM doses.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Slowed XB kinetics at the cellular level may underlie the observed prolongation of systolic ejection time at the whole-heart level after OM treatment in healthy volunteers and HF patients.
• Our results highlight the importance of administering optimal OM doses to HF patients to achieve an increase in force generation and stroke volume but avoid excessive prolongation of systolic ejection time, which can reduce time for diastolic filling.
3 as described previously. 20 Gels were scanned using Image J software.
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Preparation of Chemically Skinned Multicellular Myocardial Preparations, Ca 2+ Solutions, and OM Solutions Detergent-skinned multicellular ventricular preparations (≈100 μm in width and ≈400 μm in length) were prepared as described earlier. 18 The composition of various Ca 2+ solutions 21 used for experiments was calculated using a computer program 22 and using established stability constants.
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OM (Selleckchem, Houston, TX) and was initially dissolved in DMSO 11 and diluted in a relaxing solution to achieve final concentrations of 0.5 or 1.0 μmol/L OM. Functional measurements (Figures 2 through 5) were performed at ≈24°C after a 2-minute incubation with 0.5 or 1.0 μmol/L OM.
Stretch Activation Experiments to Measure Dynamic XB Contractile Parameters
The stretch activation protocol used here was described in detail previously. 11, 18 Skinned myocardial preparations were exposed to pCa solutions that generated ≈25% of maximal force prior to OM incubations (ie, pCa 6.6 and pCa 6.3 in HF and donor myocardium, respectively). As done earlier, 24 a lower pCa (ie, pCa 6.6) was chosen for HF group to account for an increased myofilament Ca 2+ sensitivity when compared with the donor group. The key features of cardiac muscle stretch activation responses are depicted in Figure 4A . A mechanical slack-restretch protocol was used to measure the rate of tension redevelopment, k tr , using linear transformation of the half-time of force redevelopment, that is, k tr =0.693/t 1/2 , where t 1/2 is the time (in milliseconds) required to reach half maximal force of the k tr trace. 24 
Data Analysis
Data were analyzed with a linear mixed effect model 25 with an unstructured covariance matrix across the conditions and across the groups. The R package lme4 was used to implement the linear mixed analysis. 26, 27 Asterisks in figures and tables denote statistical significance using a Tukey post hoc multiple comparisons test, and type I error was controlled by adjusting P values for multiple comparisons using a false discovery rate method. Values are reported as mean±SEM, and the criterion for statistical significance was set at P<0.05.
RESULTS

Sarcomeric Protein Expression and Phosphorylation Levels
The basal phosphorylation levels of cardiac MyBP-C (myosin-binding protein-C), TnT (troponin T), and TnI (troponin I) were reduced in HF samples compared with donor samples. Phosphorylation levels of MyBP-C, TnT, and TnI in HF were ≈65±11% (P=0.001), ≈68±10% (P=0.04), and ≈33±8% (P<0.005), respectively, compared with donor myocardium (n=4; Figure 1A and 1B). Phosphorylation levels of other sarcomeric proteins such as regulatory light chain were not significantly different between the groups. Donor and HF ventricular samples expressed 100% β-myosin heavy chain isoform without evidence of α-myosin heavy chain expression ( Figure 1C) . We have previously shown that OM incubation does not affect the phosphorylation status of sarcomeric proteins.
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Effects of OM on Ca
2+ -Activated Force Generation
Ca 2+ -activated force generation was measured in skinned ventricular myocardial preparations in a range of pCa that yielded forces below half-maximal force (ie, in pCas 6.6, 6.5, 6.4, and 6.3). Force measurements were collected at baseline or after a 2-minute incubation in 0.5 or 1.0 μmol/L OM. The increase in OMinduced force enhancement gradually decreased with increasing levels of Ca 2+ activations (Figure 2 ), as reported previously. 11 Force enhancements after 0.5 μmol/L OM incubation were ≈28±5%, 25±3%, 22±3%, and 19±4% in the donor group and ≈24±7%, 19±3%, 13±2%, and 8±2% in the HF group at pCas 6.6, 6.5, 6.4, and 6.3, respectively. Force enhancements after 1.0 μmol/L OM incubation were more pronounced: ≈85±11%, 63±9%, 54±7%, and 28±5% in the donor group and ≈78±13%, 67±17%, 36±10%, and 27±6% in the HF group at pCas 6.6, 6.5, 6.4, and 6.3, respectively. Importantly, OM-induced force enhancement was more pronounced in HF myocardium than in donor myocardium when comparisons were made at equivalent baseline levels of force production (ie, at pCa 6.6 in HF versus pCa 6.3 in donor). Furthermore, OM incubation did not alter either the Ca 2+ -independent force (ie, F min measured at pCa 9.0) or the maximal Ca 2+ -activated force (ie, F max measured at pCa 4.5) in both donor 11 and HF groups ( Table 1) .
Effects of OM on Myofilament Ca
2+
Sensitivity (pCa 50 ) and Cooperativity of Force Development (n H )
Under basal conditions, HF myocardium displayed increased pCa 50, that is, an increased responsiveness of cardiac myofilaments to Ca 2+ when compared with donor myocardium, as indicated by a significant left-ward shift in the force-pCa relationships ( Figure 3A ), a trend that was maintained even after OM incubation ( Table 1) . The increase in Ca 2+ sensitivity post-OM incubations was mainly confined to forces <40% of maximal force, and hence, pCa 50 was unaltered in both groups (Table 1; Figure 3B and 3C) . n H values decreased post-OM incubations in both groups, indicating that OM decreased the overall cooperativity of force production ( Table 1) .
Effects of OM on k tr
When studied at equivalent levels of steady-state force generation (ie, at pCa 6.3 and 6.6 in donor and HF myocardium, respectively), no differences in k tr were observed between donor and HF prior to OM incubation (Table 2) . OM differentially affected k tr in HF and the donor group after 0.5 and 1.0 μmol/L OM incubations: k tr was slowed by ≈33% and ≈32%, respectively, in the HF group but not in donor group, suggesting that OM slows XB transitions from weakly bound to strongly bound states or from strongly bound to weakly bound states, or both, resulting in an overall slowing of XB cycling in HF myocardium.
Effects of OM on Dynamic Stretch Activation Parameters
Stretch activation parameters ( Figure 4) were assessed after OM incubations (0.5 or 1.0 μmol/L) at equivalent levels of force generation (ie, at pCa 6.3 and 6.6, respectively, in donor and HF myocardium). The impact of OM on the rate of XB detachment was assessed by measuring k rel . Our findings show that donor myocardium displayed accelerated k rel (≈35%; P=0.03) and a ] activations in donor and heart failure (HF) myocardium. Baseline forces produced by the skinned myocardial preparations were first measured in Ca 2+ solutions producing a range of submaximal forces. Forces were measured at baseline or after a 2-minute incubation with 0.5 or 1.0 μmol/L OM. The net increase in force generation from the untreated baseline (pre-OM) after OM incubation was calculated and is expressed as percent increase in force from baseline. Force enhancements were pronounced at submaximal Ca 2+ activation but declined as the level of Ca 2+ was increased. Twelve skinned myocardial preparations (3 fibers each from 4 hearts) were used for both groups. *Significant force enhancement from baseline level in donor and HF myocardium after 1.0 μmol/L OM incubation, P<0.05. †Significant force enhancement from baseline level in donor and HF myocardium after 0.5 μmol/L OM incubation, P<0.05.
greater magnitude of XB detachment (P2) as indicated by more negative P2 values compared with HF myocardium (Table 2) . Interestingly, incubation with OM did not alter k rel in donor myocardium, but k rel was slowed after 1.0 μmol/L OM by ≈30% in HF myocardium, indicating a differential effect of OM on k rel in HF myocardium ( Table 2) .
The impact of OM on the rate and magnitude of XB recruitment was assessed by measuring k df and P df , respectively. k df was slowed by ≈28% and ≈44%, respectively, in donor myocardium after 0.5 and 1.0 μmol/L OM incubations. However, k df was slowed by ≈42% and ≈57%, respectively, in HF myocardium after 0.5 and 1.0 μmol/L OM incubations (Table 2) . Prior to OM incubation, donor myocardium exhibited greater P df (≈73% higher versus HF myocardium; P=0.02; Table 2 ), suggesting impairments in XB recruitment in HF myocardium. OM incubations did not affect the new steady-state force attained after the imposed stretch (ie, P3) in either group (Table 2) . P df was enhanced by ≈74% and ≈65% (P=0.02) after 0.5 and 1.0 μmol/L OM incubations in HF myocardium, respectively, such that the overall number of XBs recruited into the force-bearing state was substantially enhanced, whereas no OM-induced enhancement in P df was observed in donor myocardium (Table 2) , indicating a differential effect of OM on P df in HF myocardium.
To gain further insights into the mechanisms by which OM differentially affects XB behavior in donor and HF myocardium, we measured T rec , the time lag between k rel and k df (see Data Supplement for a detailed explanation). T rec can be interpreted as the time required for the transition between XB detachment and the commencement of XB attachment to actin because of the recruitment of XBs into the force-bearing state. T rec was not statistically different between HF and donor myocardium (Table 2; Figure 5A ) under basal conditions. Importantly, after OM incubation, HF myocardium displayed ≈47% and ≈62% increases in T rec (Table 3 ; Figure 5A ) at 0.5 and 1.0 μmol/L OM, respectively, but no effects of OM on T rec were observed in donor myocardium. Thus, T rec in HF myocardium was ≈109% and ≈149% longer than in donor myocardium after 0.5 and 1.0 μmol/L OM incubations (P<0.005; Table 3 , Figure 5A ), suggesting a differential effect of OM on T rec in HF myocardium.
No differences in T pk (ie, time to achieve peak force development) were observed between donor and HF myocardium under basal conditions, but T pk was ≈32% and ≈38% longer (P<0.005; Figures 4A and 5B) in HF myocardium versus donor myocardium after 0.5 and 1.0 μmol/L OM incubations, respectively (Table 3) . This indicates a greater delay in achievement of peak force generation in HF myocardium and, thereby, a differential effect of OM on T pk in HF myocardium. 
DISCUSSION
OM is currently in clinical trials as a potential therapy for systolic HF 6,7 because of its ability to augment acto-myosin XB interactions and force generation without the undesirable secondary effects of other inotropic agents. However, despite early evidence of the utility of OM in HF patients, the detailed mechanisms underlying OMinduced effects on XB behavior at the cellular level in HF myocardium have not been established. Here we show that OM enhances force generation in HF myocardium by shifting the XB equilibrium toward a force-bearing state; however, the time course of XB recruitment is prolonged such that achievement of peak force generation is delayed when compared with donor myocardium.
HF Myocardium Exhibits Reduced Magnitude of XB Recruitment
Poor systolic function is a common feature of HF patients, and the contractile deficits can often be traced to the contractile machinery's inability to elicit sufficient force-generating interactions between myosin and actin. Indeed, previous studies have reported contractile abnormalities in HF myocardium, 17 as evidenced by reduced maximal force generation and enhanced myofilament Ca 2+ sensitivity (ie, pCa 50 ). However, the mechanisms underlying the changes in dynamic regulation of XB behavior in HF myocardium are unknown. Consistent with previous reports, 17 we observed reduced steady-state maximal force generation and increased pCa 50 in HF myocardium when compared with donor myocardium (Table 1 ; Figure 3A ). However, unlike previous studies, 11,25 OM incubation did not enhance the pCa 50 (Table 1 ). The cause of this discrepancy is unclear, but may be related to a basal temperature-dependent sensitization of thin filaments, which act to decrease the impact of OM on pCa 50 (15°C 25 and 22°C 11 in earlier studies versus 24°C in the present study). Results from stretch activation experiments revealed a slowed rate of XB detachment (ie, k rel ; Table 2 ) in HF myocardium, which acts to prolong XB duty ratio and increase force generation at low Ca 2+ activations. Furthermore, despite a lack of difference in basal rates of XB recruitment between HF and donor myocardium (ie, k tr and k df ; Table 2 ), HF myocardium displayed impairments in the magnitude of XB recruitment (ie, P df ; Table 2 ), thereby, contributing to a reduced force-generating capacity. These findings suggest that factors inherent to HF myocardium, such as contractile protein dephosphorylation, contribute to impaired force generation. Collectively, prolonged XB on time because of slowed XB detachment and a reduced magnitude of XB recruitment are likely contributors to slowed rates of diastolic relaxation and impaired systolic function displayed by HF patients in vivo.
It is unclear why HF myocardial samples generate lower maximal forces, display slower rates of XB detachment, and recruit less XBs into force-bearing states, but these effects could be related to diminished phosphorylation of key contractile proteins, such as MyBP-C, TnI, and TnT (Figure 1) , which have been shown to be reduced in HF. 17 In particular, we have previously shown that increased MyBP-C phosphorylation by PKA (protein kinase A) accelerates the rates and enhances the magnitudes of XB detachment and recruitment, 24, 29 whereas
MyBP-C dephosphorylation slows the rates and reduces the magnitudes of XB detachment and recruitment. 18, 24 In addition, PKA-mediated TnI phosphorylation has been shown to accelerate XB detachment and decrease myofilament Ca 2+ sensitivity. 30 Thus, reduced MyBP-C and TnI phosphorylation in HF myocardium would be expected to slow the rate of XB detachment (Table 2; Figure 5 ) and decrease the number of XBs entering the cycling pool during myofilament activation. Furthermore, our finding that TnT phosphorylation is reduced in HF myocardium (Figure 1) suggests that TnT may also be a component of β-adrenergic signaling, 21 ,28 a pathway known to be downregulated during HF, 31 although the specific impact of PKA-mediated TnT phosphorylation is yet to be elucidated. Moreover, it is likely that although total TnT phosphorylation is reduced, PKCmediated TnT phosphorylation may be upregulated in HF, 32 contributing to slowed XB detachment in HF myocardium. In contrast to reduced MyBP-C, TnI, and TnT phosphorylation, we did not observe changes in regulatory light chain phosphorylation, which is consistent with our data demonstrating that baseline k df is similar in HF and donor groups (Table 2 ) because increased regulatory light chain phosphorylation would be expected to accelerate k df . 33 Additionally, it is also possible that HF myocardium harbors an increased number of super-relaxed myosin heads, characterized by substantially slower ATP turnover rates, which have been linked to reduced MyBP-C phosphorylation. 34 These super-relaxed heads are proposed to be folded over and interacting with the thick filament backbone rather than interacting with myosin-binding sites on actin, thus, potentially decreasing thin filament activation and force generation in HF myocardium, although this possibility requires further investigation. -activated force, P0, which refers to the activation level (≈25% of maximal Ca 2+ -activated force), and is equivalent in the donor and HF groups (see Methods for details). Values are expressed as mean±SEM. Twelve skinned myocardial preparations (3 fibers each from 4 hearts) were used for both groups. HF indicates heart failure; k df , rate of XB recruitment; k rel , rate of XB detachment; k tr , rate of tension redevelopment; P1, XB stiffness; P2, magnitude of XB detachment; P3, the new steady-state force attained after a 2% stretch in muscle length; P df , magnitude of XB recruitment; OM, omecamtiv mecarbil; and XB, cross-bridge.
*Different vs the corresponding pre-OM group, P<0.05. †Different vs the corresponding donor group, P<0.05.
OM Enhances the Magnitude of XB Recruitment in HF Myocardium
Earlier studies have shown that OM enhances myofilament force generation by altering the kinetic properties of the β-myosin heavy chain motor. 11, 13, 25 As shown earlier, 11 we observed that OM-induced force enhancements were primarily confined to submaximal Ca 2+ activations and that force enhancements gradually decline with increasing Ca 2+ levels ( Figure 2 ). As reported earlier, 11 OM treatment also reduced the cooperativity of force generation, n H (Table 1) , which may be related to the fact that at low [Ca 2+ ], thin filament activation relies more on XB-mediated cooperative XB recruitment as most of the regulatory units are in the off state. 35 However, as intracellular [Ca 2+ ] rises, most of the regulatory units switch to the on state, effectively reducing the dependence on XB-mediated cooperative XB recruitment, which offsets the impact of OM and decreases the overall steepness of n H . 36 In addition to enhanced force generation, OM slowed the rate of XB recruitment (k df ) ( Table 2) , which can be linked to OM's ability to shift XB equilibrium toward a force-bearing state through enhanced XBmediated cooperative XB recruitment to neighboring regulatory units, a slow and time-consuming process. At higher doses (1.0 μmol/L), OM also slowed the rate of XB detachment (k rel ) in HF myocardium (Table 2) . Thus, at higher concentrations, OM-induced force increases maybe, in part, attributed to a slowing in k rel , which concomitantly increases the time that myosin XBs remain bound to actin (increased XB duty ratio), 11, 25 an effect that has been proposed to be caused by allosteric changes in myosin heads 37 and delayed actin-induced myosin light chain domain rotation. 15 Furthermore, OM also traps a population of XBs in a weak actin-affinity state, 25 and those myosin heads may not be readily available for recruitment or they may transition toward the force-bearing state slowly-a mechanism that contributes to a prolonged time course of cooperative XB recruitment and slowing of force generation.
Importantly, when tested at equivalent submaximal activation levels, OM elicited differential effects on XB behavior in HF myocardium. Notably, the basal time course of XB recruitment to a force-generating state, T rec , was not different between donor and HF myocardium; however, after OM incubation, T rec was significantly slower in HF myocardium (Table 3) . A greater OM-induced slowing of T rec in HF myocardium would be predicted to slow the overall rate of XB cycling from a weakly bound to a strongly bound state and vice versa (k tr ). 38 Indeed, OM-induced slowing in k tr is observed in HF myocardium but not in donor myocardium (Table 2 ). An indirect effect of slowed XB cycling in HF myocardium is a further prolongation of the XB duty ratio, which acts to prolong the open state of tropomyosin, thus, permitting more XB recruitment and binding to additional open actin sites. In support of this notion, we observed that the magnitude of XB recruitment (P df ) is enhanced to a greater extent in HF myocardium compared with donor myocardium after OM incubation (Table 2) .
Our observation that OM slows XB kinetics may seem to differ from results of enzymology studies, which showed that OM accelerated the rate of phosphate release, 10, 15 which would be expected to accelerate the rate of force generation. Interestingly, although not tested at multiple doses of OM, Rohde et al 15 also showed that OM slows the force-generating myosin power stroke step by delaying the rotation of myosin light chain domain and effectively uncouples the power stroke from actin-activated phosphate release. 15 This mechanism may resolve the seemingly contradictory findings that OM accelerates phosphate release, yet slows XB kinetics, as we show here. An additional consideration in analyzing results of OM experiments is that some studies have used systems that lack an intact myofilament lattice, 10, 13, 15 in contrast to skinned myocardium used here. Notably, ADP release is a strain-sensitive mechanism, 39 a property that would be difficult to capture using unregulated systems. Nevertheless, studies using regulated systems (ie, in vitro motility assays or skinned myocardium) reported slowed rates of shortening velocity and XB detachment, 11, 13, 14 suggestive of a slowed ADP release (although this was not directly measured in these studies). Collectively, these findings suggest that OM acts to slow the rate of XB transitions to force-bearing states and prolongs XB duty cycle, which together act to promote XB-mediated cooperative XB recruitment and slow the rate of force generation, as observed in our studies.
Another key finding is that despite a significant OM-induced enhancement in the magnitude of XB recruitment, HF myocardium displayed a delay in achievement of peak force development, T pk , when compared with donor myocardium, in part, because of a prolongation of T rec in HF myocardium (Table 3 ; Figure 5 ). Collectively, these findings suggest that the beneficial effects of OM manifest more slowly in the HF myocardium. This differential response to OM may be because of inherent deficits in force-generating capacity in HF myocardium, such as reduced numbers of readily available XBs for recruitment, impaired XB cycling because of contractile protein dephosphorylation, or both.
Potential In Vivo Consequences of OMInduced Effects on XB Behavior
OM differentially impacts HF myocardium, in that there is a greater slowing of cooperative XB recruitment, T rec , and a greater prolongation of the time to reach peak force development, T pk -a cumulative impact is a substantially enhanced XB recruitment, P df , in HF myocardium. The differential dose response to OM may be related to inherent differences in basal contractile function in donor and HF myocardium and has significant implications for in vivo contractile function in HF patients. Specifically, during the initial phase of the isovolumic contraction, the Ca 2+ levels surrounding the myofilaments is low. 40 Because the effects of OM are more prominent at low Ca 2+ levels, OM treatment enhances XB recruitment and amplifies the number of XBs ultimately participating in force generation during this initial phase of isovolumic contraction, thereby, augmenting ventricular pressure development later in systole. 10 Specifically, our data show that a higher OM dose (1.0 μmol/L), which may be greater than the effective doses administered to HF patients in clinical trials to date, 6, 7 results in robust enhancements in force generation, but also significantly slows XB detachment (k rel ) in HF myocardium. Slowed k rel likely plays a major role in determining the total SET and the commencement of ventricular relaxation and diastolic filling. 41 In particular, in the late systolic ejection phase, during which a substantial amount of blood is pumped into the circulation, the Ca 2+ transient wanes off 42 and XBs begin to rapidly detach because of shortening-induced cooperative deactivation of the thin filaments. 40 Thus, slowed k rel at higher OM doses may act to prolong XB-mediated thin filament activation, which is a net effect of all bound XBs, thereby, prolonging the SET-potentially delaying ventricular pressure decay and reducing diastolic filling. 41 In contrast, incubations of skinned myocardium with 0.5 μmol/L OM produced relatively smaller enhancements in force generation, but did not slow k rel , suggesting that it is possible to optimize OM dose to elicit beneficial effects on systolic force generation without the potential adverse impact of excessive prolongation of SET that can infringe on the diastolic filling phase.
Study Limitations
It is important to note that our in vitro experiments cannot fully account for a slew of complexities that are inherent to clinical HF studies, such as alterations in neurohormonal signaling, Ca 2+ cycling, and posttranslational modifications in noncontractile proteins that typically occur in a remodeled HF myocardium. Furthermore, our experiments cannot specifically account for various comorbidities, such as diabetes mellitus, hypertension, and peripheral arterial disease, or supplementary pharmacological interventions, such as diuretics, angiotensin-converting enzyme inhibitors, β-blockers, and so on, that may be administered to HF patients in addition to OM. 6 All the above factors may influence the in vivo impact of OM to some degree and cannot be fully recapitulated in vitro. Thus, caution should be exercised when extrapolating our data to clinical outcomes.
Conclusions
Our novel findings demonstrate that OM promotes XB formation but prolongs the time course of cooperative XB recruitment, leading to delayed peak force development in HF myocardium when compared with donor myocardium. At higher doses of OM, slower rates of force development are also accompanied by slower rates of XB cycling, which may underlie the prolongation of SET in vivo. Of clinical significance, our results demonstrate that correct OM dosing may be critical to achieve a balance of increased systolic performance without diminished diastolic filling in vivo.
